Bispecifics, BTK Inhibitors, and Immunotherapy Drive Lymphoma Advances
Bispecifics, BTK Inhibitors, and Immunotherapy Drive Lymphoma Advances

Julie Vose, MD, MBA, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Insights on CAR-NK Therapy and Hodgkin Lymphoma Updates at ASH 2025
Insights on CAR-NK Therapy and Hodgkin Lymphoma Updates at ASH 2025

Sam Yamshon, MD, Andrew Evens, DO, MBA, MSc

Oncologists Review Practice-Changing Lymphoma Findings From ASH 2025
Oncologists Review Practice-Changing Lymphoma Findings From ASH 2025

Kingsley Nnawuba, MD, Urshila Durani, MD, MPH

Experts Discuss Sonrotoclax and Lymphoma Trials at ASH 2025
Experts Discuss Sonrotoclax and Lymphoma Trials at ASH 2025

Agrima Mian, MD, Sam Yamshon, MD

Primary Results From EPCORE FL-1 Presented at ASH 2025
Primary Results From EPCORE FL-1 Presented at ASH 2025

Urshila Durani, MD, MPH, Joshua Brody, MD